Alto Neuroscience, Inc. (NYSE:ANRO) Receives Average Rating of "Moderate Buy" from Brokerages

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $20.00.

A number of equities research analysts have recently weighed in on ANRO shares. Robert W. Baird dropped their price target on Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Stifel Nicolaus lowered their target price on Alto Neuroscience from $32.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 13th. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. Wedbush downgraded Alto Neuroscience from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Finally, Rodman & Renshaw cut Alto Neuroscience from a "buy" rating to a "neutral" rating in a report on Wednesday, October 23rd.

Alto Neuroscience Price Performance

ANRO stock traded down $0.19 during trading on Friday, hitting $3.99. 207,393 shares of the company's stock traded hands, compared to its average volume of 217,736. Alto Neuroscience has a 1 year low of $3.56 and a 1 year high of $24.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The business has a fifty day simple moving average of $4.24 and a two-hundred day simple moving average of $8.01.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.67) by $0.05. As a group, sell-side analysts predict that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently bought and sold shares of ANRO. Geode Capital Management LLC increased its position in shares of Alto Neuroscience by 148.7% in the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company's stock worth $5,378,000 after acquiring an additional 281,018 shares in the last quarter. State Street Corp boosted its holdings in shares of Alto Neuroscience by 123.7% in the 3rd quarter. State Street Corp now owns 236,857 shares of the company's stock valued at $2,710,000 after buying an additional 130,985 shares during the period. Jennison Associates LLC boosted its position in Alto Neuroscience by 80.3% during the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company's stock valued at $9,521,000 after purchasing an additional 370,612 shares during the period. Franklin Resources Inc. grew its position in shares of Alto Neuroscience by 95.3% during the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock worth $13,965,000 after acquiring an additional 595,673 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Alto Neuroscience in the third quarter valued at approximately $124,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.